|
|
||||||||
From the Headache Unit, Neurology Division, Internal Medicine Department, Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil (Drs. Piovesan, Teive, Kowacs, Della Coletta, and Werneck); and Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA (Dr. Silberstein).
Address correspondence and reprint requests to Dr. Elcio J. Piovesan, Headache Unit, Neurology Division, Internal Medicine Department, Hospital de Clinicas da Universidade Federal do Parana, Rua Joinvile2526, Sao Jose dos Pinhais, PR Brazil 83020 000; e-mail: piovesan1{at}hotmail.com or piovesan{at}avalon.sul.com.br
Thirteen subjects with trigeminal neuralgia were treated with botulinum-A neurotoxin (BoNT/A) in an open-label pilot study. After BoNT/A, visual analog scale score, surface area of pain, and therapeutic coefficient were reduced in all patients and for all branch trigeminal nerves studied. Therefore, BoNT/A is an efficient treatment. There were no major side effects. A placebo-controlled clinical trial is needed to confirm these findings.
Disclosure: The authors report no conflicts of interest.
Received October 12, 2004. Accepted in final form July 8, 2005.
Related Article
Neurology 2005 65: 1148-1149.
This article has been cited by other articles:
![]() |
R. Y. Yuan, J. J. Sheu, J. M. Yu, W. T. Chen, I. J. Tseng, H. H. Chang, and C. J. Hu Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial Neurology, April 28, 2009; 72(17): 1473 - 1478. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Brenner, B. Voller, T. Sycha, B. Gustorff, G. Kranz, E. Auff, J. M. Zakrzewska, J. Cohen, J. Brown, J. Alksne, et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology, May 9, 2006; 66(9): 1458 - 1459. [Full Text] [PDF] |
||||
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |